

Cadila Healthcare Ltd. - Consolidated Gross Sales Break-up

Rs. Mio.	Q3 14-15	Q3 13-14	% Gr y-y	YTD 14-15	YTD 13-14	% Gr y-y
Domestic	8,464	7,658	10.5%	26,007	23,751	9.5%
Formulations	6,418	5,890	9.0%	19,975	18,405	8.5%
API	225	112	101.1%	722	431	67.5%
Wellness	1,140	1,034	10.3%	3,317	3,223	2.9%
Animal Health & Others	680	622	9.3%	1,993	1,692	17.8%
Exports	12,298	10,056	22.3%	34,061	25,426	34.0%
Formulations	11,428	9,162	24.7%	31,530	22,872	37.9%
US	8,959	6,316	41.8%	24,144	14,921	61.8%
Europe	847	1,186	-28.6%	2,635	3,056	-13.8%
Japan	0	145	-100.0%	0	397	-100.0%
Latin America	610	687	-11.3%	1,801	1,864	-3.4%
Emerging Mkts & Others	1,013	827	22.5%	2,950	2,633	12.0%
API	734	731	0.4%	2,131	2,127	0.2%
Animal Health & Others	136	163	-16.5%	400	427	-6.3%
JVs & Alliances	1,217	1,012	20.2%	3,542	3,388	4.6%
Total	21,979	18,726	17.4%	63,610	52,564	21.0%

Cadila Healthcare Ltd.

Details of other incomes

Rs. Mio.	Q3 14-15	Q3 13-14	% Gr y-y	YTD 14-15	YTD 13-14	% Gr y-y
Other Operating Income	299	337	-11.3%	1,041	1,118	-6.9%
Royalty Income	93	51	82.4%	382	226	69.0%
Net Gain on foreign currency transactions and translation (Refer Note below)	-3	111	-103.0%	0	286	-100.0%
Others	209	175	19.4%	659	606	8.7%

Note : Apart from this loss, there was a net gain of Rs. 47 Mio. on translation of inventories held by foreign subsidiaries, which has been included in Cost of Goods and a net loss of Rs.16 Mio. included in other expenses in Q3 14-15. Thus, on aggregate level, there was a gain of Rs. 28 Mio. on operating transactions (above EBIDTA line) in Q3 14-15 vs loss of Rs. 448 Mio. in Q3 13-14. See details below for more clarity.

Rs. Mio.	Q3 14-15	Q3 13-14	% Gr y-y	YTD 14-15	YTD 13-14	% Gr y-y
Other Income	100	128	-21.7%	350	375	-6.7%
Interest & Dividend income	90	93	-3.9%	281	273	3.2%
Profit on sale of investments	2	21	-92.1%	28	58	-51.1%
Profit on sale of assets	2	0		2	0	
Others	7	14	-46.5%	39	45	-13.1%

Details of Foreign Exchange Fluctuations

Rs. Mio. (+ = loss, - = gain)	Q3 14-15	Q3 13-14	% Gr y-y	YTD 14-15	YTD 13-14	% Gr y-y
A. On operating transactions (above EBIDTA line)	-28	448	-106.1%	-74	203	-136.5%
a. Included in other income	3	-111	103.0%		-286	100.0%
b. Included in sales		223	-100.0%		550	-100.0%
c. Included in cost of goods	-47	336	-114.0%	-90	-61	-47.5%
d. Included in other expenses	16			16		
B. On Foreign Currency Borrowings (part of interest cost)	25	-103	124.3%	24	-247	109.7%
Total Foreign Currency Fluctuations (+ = loss, - = gain)	-3	345	-100.7%	-50	-44	-13.6%

Details of R&D Expenses

Rs. Mio.	Q3 14-15	Q3 13-14	% Gr y-y	YTD 14-15	YTD 13-14	% Gr y-y
Total R&D Expenses	1,883	1,234	52.7%	4,118	3,575	15.2%

Consolidated Capex for Apr-Dec 14

Rs. 2750
Mio.

R&D capex included in above for Apr-Dec 14

Rs. 118
Mio.